A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.
Study Number: SCRI CA2660001
Study Summary:
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Status: Open
Study Coordinator(s)
- Angie, 309-243-3613, aearles@illinoiscancercare.com
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
- Heather, 309-243-3661 hthulean@illinoiscancercare.com
